Binding of the papillomavirus E6 protein to E6AP and induction of p53 degradation is a common feature of genital high-risk human papillomaviruses (HPV), but cutaneous HPV lack this capacity. Nevertheless several cutaneous HPV types like HPV38 are associated with tumor formation when combined with a genetic predisposition, immunosuppression or UVexposure. In an animal model system, the cottontail rabbit papillomavirus (CRPV) rapidly induces skin cancer without additional cofactors and CRPVE6 and E7 immortalize rabbit keratinocytes in vitro. However, CRPVE6 neither interacts with E6AP, with p53 nor induces p53 degradation. In this study, we show that interaction of CRPV or HPV38E6 with the histone acetyltransferase p300 is crucial to inhibit the ability of p53 to induce apoptosis. Strikingly, E6 mutants deficient for p300 binding are incapable of preventing p53 acetylation, p53 dependent transcription and apoptosis induction. Moreover E6 mutants deficient for p300 binding can not contribute to HPV38-induced immortalization of human keratinocytes or CRPV-induced tumor formation.
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Copyright © 2010 American Association for Cancer Research aliquot of the cell lysates was removed (input control) and the rest of the lysates were mixed with 50µl pre-washed µMACS Anti-HA Micro Beads (Miltenyi Biotec) and incubated for 3h at 4°C. Beads were collected in µColumns (Miltenyi Biotec) and washed 5 times with IPbuffer. Bound proteins were eluted with 4xSDS sample buffer (95°C) and analysed by immunoblotting.
Animal model
Infections of New Zealand White rabbits with CRPV DNA were performed as previously described (10) . Tumor numbers and maximum diameter of each tumor were determined over a period of 5 months. Biopsies were removed 3 months post infection, embedded in Tissue-
Tek O.C.T. compound (Sakura Finetek), snap-frozen, and stored at -80°C or DNA was extracted using a BioRobot EZ1 workstation with the EZ1 DNA Tissue Kit (Qiagen). Viral DNA was amplified using primers CRPV444-463F and CRPV1124-1104R and sequenced.
Immunofluorescence microscopy and TUNEL staining
Cells were grown on MatTek glassbottom culture dishes (MatTek Corporation MicroImaging GmbH). For each sample, at least 5 different fields were examined and counted to determine the rate of apoptosis.
Western Blotting
Cells were lysed in RIPA buffer (Sigma). Normalized amounts of protein (Micro BCA protein assay reagent kit; Thermo Scientific) were separated by 10% SDS-PAGE and transferred to nitrocellulose. Primary antibodies were: α-p53 (DO-1, Santa Cruz); α-p53-Lys382 (2525S, New England Biolabs), α-Tubulin (DM1A, Merck) or α-GFP (FL 32, Santa Cruz). Secondary antibodies conjugated to horseradish peroxidise (Dako) were detected using SuperSignal West substrates (Thermo Scientific) and a Fluor-S Max MultiImager (Bio-Rad). MBP pulldown and coimmunoprecipitation eluates were run on 5-12% SDS-polyacrylamide gels and transferred to nitrocellulose. The membranes were probed with antibodies detecting p300 (C-20, sc-585 (Santa Cruz); ab37142; ab10485 (both Abcam)) and MBP (E8038 (New England Biolabs)).
Blots were developed with SuperSignal West (Thermo Scientific) substrate and visualized by the Fluor-S Max MultiImager (Bio-Rad). Band intensities were quantified using the Quantity One quantification software package (version 4) (Bio-Rad).
Results

P53 is not degraded by E6 proteins of cutaneous papillomaviruses
The addition of the proteasome inhibitor MG132 to CRPV and HPV38 E6/E7 immortalized keratinocytes has indicated that the respective E6 proteins do not induce p53 degradation (12, 24) . To further confirm these findings, HPV16, HPV38 or CRPV E6/E7 immortalized keratinocytes were treated with cycloheximide, an inhibitor of protein biosynthesis (Fig 1A) . 
CRPVE6 represses transcriptional activity of p53
To evaluate if rabbit p53 (rp53) is similar to human p53 (hp53) with regard to transcriptional activation, we expressed rp53 and hp53 in p53-deficient Saos-2 cells and tested for p21 induction. After 48 hours a 4-fold induction of p21 was observed by rp53 and hp53. P21-induction of rp53 was strongly impaired by cotransfection of CRPVE6 (Fig. 1B) although it does neither interact with nor degrade p53 (12, 20, 21) .
CRPVE6 interacts with p300
Immobilized E6 proteins fused to maltose-binding protein (MBP) were incubated with HEK293T cell extracts containing high amounts of p300 protein. Similar to high-risk HPV, CRPV encodes two forms of E6. Short E6 (SE6) is generated by the second methionine (M98) within the full length E6 (long E6, LE6). Both CRPVE6 proteins revealed a much stronger interaction with p300 than the E6 proteins of HPV11, 16 or 18 ( Fig 1C) . As the smaller SE6 protein also bound p300 this indicated that the binding motif is located within a region common to both proteins.
The interaction of HPV16E6 with p300 was described to rely on glycine 134 (G134), which is conserved among genital HPVE6 proteins (28, 38) . The corresponding glycine at position 135 (CRPVLE6) and 38 (CRPVSE6) was replaced by valine (MBP-SE6 G38V) ( G134 and corresponding glycines underlined) and tested for interaction with p300 by MBP pulldown assays (Fig. 1D) . Surprisingly, both wildtype CRPVSE6 and the mutant SE6 G38V bound comparable amounts of p300 suggesting that the CRPVE6 interaction domain with p300 is different from HPV16E6.
Identification of the p300-binding region within CRPVE6
As both LE6 and SE6 interact with p300, we generated subfragments of SE6 to map the interaction domain by MBP pulldown assays (Fig 2A) . For better understanding, the amino acid positions are based on the respective amino acids in the full length CRPVE6 protein (LE6). The minimal interaction domain consisted of aa 166-214 (Fig. 2B ). Further C-or Nterminal truncations (aa 178-214 or aa166-197) resulted in a complete loss of p300 binding.
To further narrow down the binding motif, we performed an alanine scanning mutagenesis of aa 166-178 and aa197-214 by replacing four to five consecutive residues with alanines ( protein. This is similar to the background p300-binding activity of MBP (9% of wt SE6).
To verify this, we performed a co-immunoprecipitation with an HA-tagged CRPV full length E6 protein ( E6M98SHAAla195-199 or E6M98SHAAla200-204 mutants were transfected into C33A cells. Cell lysates were precipitated with HA-antibody and the immunoprecipitates were analyzed for p300 by immunoblotting. Only the HA-tagged wildtype E6 protein was able to precipitate p300. The mutant E6 proteins were present even at higher levels than the wildtype , but did not immunoprecipitate p300 (Fig. 2C ). These results demonstrate that CRPVE6
interacts with p300 and that residues 195-204 are crucial for this interaction and do not impair protein stability. Immunofluorescence analyses revealed that wtE6 and both mutants (E6Ala195-199, E6Ala200-204) were present in the nucleus and to a minor extent in the cytosol ( Fig. 2D ) which is consistent with previous reports (21) . Localization of E6M98SHAAla195-199 and E6M98SHAAla200-204 were indistinguishable from E6M98SHA. From these data, we conclude that these mutations in LE6 specifically prevent interaction with p300 but do not change subcellular localization.
Interaction of CRPVE6 with p300 inhibits p53 acetylation
Four different siRNAs against p300 were constructed and tested for their protein knockdown efficiency ( Fig. 3A upper panel) . The most effective siRNA (sip300-2) was further tested for p300 mRNA reduction (Fig 3A middle panel) and further used for the functional assays. The knock-down of p300 reduced p21 induction by rabbit and human p53 2-3 fold ( Fig. 3A lower panel). It is known that p300 acetylates p53 at lysine-382 which stabilizes binding to the p21
promoter (39) . Therefore we exchanged the corresponding lysine-380 in rp53 to arginine (rp53K380R). In contrast to wildtype rp53, rp53R380K no longer induced p21 transcription in Saos-2 cells (Fig. 3B ). This indicated that rp53 like hp53 depends on p300 as a coactivator.
We then transfected Saos-2 cells with hp53 and CRPVE6 and analyzed the amount of p53 and p53 acetylated at lysine-382 ( CRPVE6 revealed similar amounts of total p53. However, coexpression of CRPVE6 led to a loss of p53 acetylation at K382. When we cotransfected the p300 binding deficient CRPVE6 (E6M98SAla200-204), acetylated hp53 was clearly visible, indicating that the interaction of wildtype CRPVE6 with p300 is responsible for inhibition of p53 acetylation.
CRPVE6 inhibits p53 induced apoptosis
As E6 prevents acetylation of p53 by p300 and therefore p21 induction, we next investigated the effect of CRPVE6 on p53-mediated apoptosis. Saos-2 cells were cotransfected with expression vectors for hp53, rp53, rp53K380R and wt CRPVE6 or E6M98SAla200-204.
Rp53 and hp53 induced similar numbers of apoptotic cells (19%) as determined by TUNEL staining whereas rp53R380K did not (9.7 ± 1.3%) (Fig. 3D) . Interestingly, coexpression of CRPVE6 reduced apoptosis induction by rp53 to 10.8 ± 2.6%, whereas E6M98SAla200-204 did not (20.4 ± 1.3%). This suggests that the ability of CRPVE6 to abrogate p300-mediated acetylation of p53 is crucial for cell survival.
E6-p300 binding is important for carcinogenesis
To analyze the importance of the ability of E6 to bind p300 and inhibit the acetylation of p53
in vivo, we created p300-binding deficient (pLA2-CRPVE6Ala195-199 and pLA2-CRPVE6Ala200-204) and competent (pLA2-CRPVE6Ala210-214) E6 mutant proteins in the context of the CRPV genome. Wildtype and mutant CRPV genomes were each injected at six sites in the skin of the back of two New Zealand white rabbits. Tumor development and growth were monitored for five months. Wildtype CRPV and pLA2-CRPVE6Ala210-214 produced tumors comparable in size and growth at all injection sites in both animals ( Fig. 4A ; Table 2 ). The tumors induced by the mutant viruses retained their slower growth over the course of the experiment (Fig 4A,   Table 2 ). To examine if the reduced growth rate of the tumors was due to increased apoptosis, biopsies were taken 85 days post infection. Cryo-sections of the biopsies were TUNELstained for apoptotic cells and analyzed by fluorescence microscopy. Whereas the tumors from both wildtype and pLA2-CRPVE6Ala210-214 genomes showed no signs of apoptotic cells, the tumors induced by p300-binding-deficient genomes showed increased numbers of apoptotic cells (Fig 4B) . CRPVE6/E7 genes were subjected to sequence analysis which revealed that only the introduced mutations but no other mutations in the E6/E7 region were present in the tumor cells. This strongly suggests that the retarded tumor growth is a consequence of increased apoptosis due to a lack of interaction between CRPVE6 and p300. is able to interact with p300 and whether this interaction is mediated by aa 81-83, wildtype and a mutant HPV38 E6 (HPV38 E6Ala80-84) were expressed as MBP fusion proteins.
Pulldown experiments revealed that p300 bound to HPV38E6, but not to the mutant (Fig 5A) .
In contrast, both the wildtype and the mutant HPV38 E6 protein bound to E6AP (40) ,
suggesting that the mutation is specific for p300 (Fig. 5A) . Consistent with the observations
Discussion
While epidemiological studies hint to a possible role for HPV types of the β2-genus in the development of skin cancer (8) the underlying molecular mechanisms are not understood in great detail. Recent work has suggested that the E7 proteins of CRPV and the skin-cancer associated ß2-subgenus type HPV38 interfere with pRB function similar to HPV16 and 18 (12, 22) . In contrast, very little is known about how these viruses prevent p53 mediated apoptosis provoked by E7-activated E2F proteins (41) . The E6 proteins of both viruses lack the ability to degrade p53 (21, 22) , indicating that they rely on alternative mechanisms to inactivate p53.
To address differences or mutations in the rabbit p53 that shares 85% aa identity with human p53, we analyzed rp53 DNA sequences from the immortalized rabbit keratinocytes and tumors of different stages and found only silent mutations in comparison to the reference (NM_001082404; data not shown). Furthermore, in this report we demonstrate that rp53 is very similar to hp53 with regard to p21 and apoptosis induction and the dependance upon acetylation by p300.
Both E6 of CRPV and HPV38 were able to prevent p300-mediated acetylation of p53 at lysine 382, probably through a direct interaction with p300. Interestingly we were able to detect weak p53 acetylation in Saos-2 cells transfected with p53 without using HDAC inhibitors that are commonly used to detect p53 acetylation. (39) Recently it has been shown that loss of acetylation completely abolishes p53-dependent growth arrest and apoptosis (33) . Acetylation of p53 abrogates Mdm-2 mediated repression by blocking the recruitment of Mdm2 and Mdmx to p53 responsive promoters (42) (43) (44) . The six carboxy-terminal lysines of human p53 including K382 are acetylated by p300/CBP (45).
In addition, lysine-120 is acetylated by Tip60/hMOF and lysine-164 by p300/CBP (33). Whereas it seems that some acetylation defects in human p53 can be compensated by the modification of other sites, loss of acetylation at all major sites completely abolishes the ability of human p53 to activate p21 (33) . In contrast just the rp53K380R mutation showed a major effect on p21 and apoptosis induction in Saos-2 cells, which could indicate a central role of this lysine for rabbit p53-induced apoptosis. As seven out of eight possible lysines of human p53 can be acetylated by p300/CBP (33, 45) and we demonstrated that E6 prevents p300-mediated acetylation it is conceivable that also the acetylation of other lysines by p300
is impeded. This needs to be tested in further experiments. In that case, however, lack of acetylation at the C-terminus may allow increased ubiquitination of p53 by Mdm2 and thereby affect p53 stability, which is clearly not the case in CRPV or HPV38 immortalized keratinocytes. The ubiquitin ligase activity of Mdm2 could, however, at least in CRPV immortalized cells be inhibited by the high rp19Arf levels (12) . p53 hypoacetylation mediated by E6 could then allow binding of p53 together with Mdm2 and Mdmx to p53-responsive promoters and thereby prevent transcription of proapoptotic genes, which would explain the effects we observed in this work. In addition it has been recently shown that acetylation at K320, K373 and K382 is required for the transcription independent pro-apoptotic functions of p53 at the mitochondrion (46). Whether this also contributes to the anti-apoptotic effects of CRPVE6 remains to be determined.
Two known CRPV strains with low or high tumor progression potential show aa exchanges (Q225L or G200D) in the carboxy-terminal part of E6 (47), which is the newly identified p300 interaction domain. The reduced carcinogenicity of the E6G200D genome probably results from a decreased E6-p300-interaction as indicated by our data and as a consequence increased expression of p53-dependent proapoptotic target genes. immortalized keratinocytes and induces ΔNp73, but is unable to displace ΔNp73 from p53 responsive promoters (24) . This is consistent with our findings as binding of p53 to its responsive promoters is dependent upon the acetylation state (45, 48) . The observed lack of immortalization of keratinocytes by a p300-binding deficient HPV38E6 could be due to acetylation of p53 by p300 which then can overcome the ΔNp73 blockage and induce senescence or apoptosis. Interestingly the cutaneous PV types behave similar to the adenoviral E1A protein, which binds to the TAZ2 domain of p300/CBP and competes with p53 for p300 binding (49) . Even though the binding domain of E1A shows only little overall homology to the CRPV or HPV38 E6 p300 binding domain, all three proteins contain a hydrophobic residue followed by phenylalanine. One difference between CRPVE6 and the cutaneous HPVE6 proteins is the ability of the latter ones to bind E6AP, which makes them capable of degrading the UV-induced Bak protein to escape induction of apoptosis. For CRPV such a function is not required as the fur of the rabbit protects the skin from UVirradiation.
It has been described that genital HPV types that inactivate p53 via E6AP-dependent degradation also prevent p300-mediated acetylation of p53. However, these E6 proteins differ from CRPV and HPV38 E6 because they can bind to p53 and form trimeric complexes with p53 and p300 (28) . The HPV16E6 protein interacts with the N-terminal CH1 and with Cterminal regions of p300/CBP, including the TAZ2 domain (27, 29) . The mechanism of p53 
Copyright © 2010 American Association for Cancer Research inactivation obviously differs from E1A, as HPV16E6 still requires p53 binding to repress its transcriptional activity. Furthermore the interaction domain described for HPV16E6 with p300 is different from the one we identified for CRPV and HPV38E6. For HPV16E6 residue G134 within the second zinc finger domain was described to be important (28) . However, this mutation has not only been described to be impaired for p300 binding, but also for E6AP and p53 binding and degradation (38) . The benefit of p300-mediated p53 inactivation for HPV16
and 18 is puzzling as they, in contrast to CRPV and HPV38 E6, predominantly inactivate p53 via degradation, suggesting that repression of p300-mediated p53 acetylation might be necessary for its ubiquitination by E6AP. This was reported for Mdm2-mediated p53 degradation (50) . Alternatively, p300-inhibition might be necessary to maintain residual undegraded p53 in an inactive state prior to its degradation.
In summary this is the first report demonstrating that the E6 protein of skin cancer-associated papillomaviruses mainly target p53 acetylation and not degradation of p53 via binding to p300 to immortalize primary keratinocytes and to induce tumors in an in vivo situation. A pLA2-CRPV 6/6 pLA2-CRPV E6Ala195-199 0/6 pLA2-CRPV E6Ala200-204 0/6 pLA2-CRPV E6Ala210-214 6/6 38 B pLA2-CRPV 6/6 pLA2-CRPV E6Ala195-199 0/6 pLA2-CRPV E6Ala200-204 0/6 pLA2-CRPV E6Ala210-214 6/6 55 A pLA2-CRPV 6/6 pLA2-CRPV E6Ala195-199 0/6 pLA2-CRPV E6Ala200-204 0/6 pLA2-CRPV E6Ala210-214 6/6 54 B pLA2-CRPV 6/6 pLA2-CRPV E6Ala195-199 0/6 pLA2-CRPV E6Ala200-204 0/6 pLA2-CRPV E6Ala210-214 6/6 * see figure 4A on April were passaged and total cell number was counted and extrapolated. 
